Following on from information provided to NICE by the company in December 2017, the appraisal of Selumetinib for treating differentiated thyroid cancer [ID1079] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1079

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in December 2017, the appraisal of Selumetinib for treating differentiated thyroid cancer [ID1079] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in December 2017, the appraisal of Selumetinib for treating differentiated thyroid cancer [ID1079] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
02 August 2017 In progress. In progress

For further information on our processes and methods, please see our CHTE processes and methods manual